TY - JOUR
T1 - Methionyl human growth hormone and oxandrolone in Turner syndrome
T2 - Preliminary results of a prospective randomized trial
AU - Rosenfeld, Ron G.
AU - Hintz, Raymond L.
AU - Johanson, Ann J.
AU - Brasel, Jo Anne
AU - Burstein, Stephen
AU - Chernausek, Steven D.
AU - Clabots, Teresa
AU - Frane, James
AU - Gotlin, Ronald W.
AU - Kuntze, Joyce
AU - Lippe, Barbara M.
AU - Mahoney, Patrick C.
AU - Moore, Wayne V.
AU - New, Maria I.
AU - Saenger, Paul
AU - Stoner, Elizabeth
AU - Sybert, Virginia
PY - 1986/12
Y1 - 1986/12
N2 - Seventy girls with Turner syndrome, 4 to 12 years of age, were randomly assigned to receive either no treatment (control) or methionyl human growth hormone (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination hGH plus oxandrolone therapy. Baseline growth rates averaged 4.3 cm/yr, and all were within 2 SD of mean growth velocity for age in giris with Turner syndrome. Sixty-seven giris remained in the study for a minimum of 1 year. Growth rates and growth velocity (in standard deviations for age in girls with Turner syndrome) were control 3.8 cm/yr (-0.1 SD), hGH 6.6 cm/yr (+2.3 SD), oxandrolone 7.9 cm/yr (+3.7 SD), and combination therapy 9.8 cm/yr (+5.4 SD). Mean bone ages advanced 1.0 years (hGH), 1.3 years (oxandrolone), and 1.6 years (combination). However, median increments in height age/bone age (ΔHA/ΔBA) ratios ranged from 1.0 to 1.1 for treatment groups, compared with 0.8 for the controls. Predicted adult height by the method of Bayley-Pinneau increased 2.5 cm for hGH or oxandrolone alone, and 3.2 cm for combination treatment. These data indicate that both hGH and oxandrolone can significantly stimulate short-term skeletal growth in patients with Turner syndrome, and potentially increase final adult height.
AB - Seventy girls with Turner syndrome, 4 to 12 years of age, were randomly assigned to receive either no treatment (control) or methionyl human growth hormone (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination hGH plus oxandrolone therapy. Baseline growth rates averaged 4.3 cm/yr, and all were within 2 SD of mean growth velocity for age in giris with Turner syndrome. Sixty-seven giris remained in the study for a minimum of 1 year. Growth rates and growth velocity (in standard deviations for age in girls with Turner syndrome) were control 3.8 cm/yr (-0.1 SD), hGH 6.6 cm/yr (+2.3 SD), oxandrolone 7.9 cm/yr (+3.7 SD), and combination therapy 9.8 cm/yr (+5.4 SD). Mean bone ages advanced 1.0 years (hGH), 1.3 years (oxandrolone), and 1.6 years (combination). However, median increments in height age/bone age (ΔHA/ΔBA) ratios ranged from 1.0 to 1.1 for treatment groups, compared with 0.8 for the controls. Predicted adult height by the method of Bayley-Pinneau increased 2.5 cm for hGH or oxandrolone alone, and 3.2 cm for combination treatment. These data indicate that both hGH and oxandrolone can significantly stimulate short-term skeletal growth in patients with Turner syndrome, and potentially increase final adult height.
UR - http://www.scopus.com/inward/record.url?scp=0022979669&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(86)80272-4
DO - 10.1016/S0022-3476(86)80272-4
M3 - Article
C2 - 3537249
AN - SCOPUS:0022979669
SN - 0022-3476
VL - 109
SP - 936
EP - 943
JO - Journal of Pediatrics
JF - Journal of Pediatrics
IS - 6
ER -